Claims for Patent: 7,985,745

Summary for Patent: 7,985,745

Title:	Method for pain treatment
Abstract:	This invention discloses a method of treating pain by administering histamine H.sub.4 receptor ligands and compositions comprising the same.
Inventor(s):	Cowart; Marlon D. (Round Lake Beach, IL), Altenbach; Robert J. (Chicago, IL), Liu; Huaqing (Buffalo Grove, IL), Drizin; Irene (Wadsworth, IL), Wishart; Neil (Jefferson, MA), Babinski; David J. (Dallas, TX), Gregg; Robert J. (Libertyville, IL), Hancock; Arthur A. (Libertyville, IL), Hancock, legal representative; Kathryn J. (Libertyville, IL), Esbenshade; Timothy A. (Schaumburg, IL), Hsieh; Gin C. (Long Grove, IL), Brioni; Jorge D. (Vernon Hills, IL), Honore; Marie P. (Evanston, IL), Black; Lawrence A. (Libertyville, IL), Zhao; Chen (Libertyville, IL), Wakefield; Brian D. (Evanston, IL)
Assignee:	Abbott Laboratories (Abbott Park, IL)
Application Number:	11/863,925
Patent Claims:	1. A method of treating pain comprising administering to a subject a therapeutically effective amount of a compound of Formula (VI): ##STR00045## or a pharmaceutically acceptable salt thereof, wherein: G.sub.1 is alkylene; G.sub.2 is alkylene; wherein each carbon of the alkylene G.sub.1 and G.sub.2 may be optionally substituted with one or more groups selected from alkyl, fluoroalkyl, cyanoalkyl, cycloalkyl, fluorocycloalkyl, cycloalkoxyalkyl, alkylcycloalkyl, alkylfluorocycloalkyl, fluorine, acyl, acyloxy, alkenyl, alkoxy, alkoxyalkoxy, alkoxyalkyl, alkoxycarbonyl, alkylcarbonyl, alkylsulfonyl, alkynyl, amido, carboxy, cyano, fluoroalkoxy, formyl, haloalkoxy, haloalkyl, halogen, hydroxy, hydroxyalkyl, mercapto, nitro, alkylthio, and oxo, R.sub.1 is selected from H, NH.sub.2, --NH (acyl), --NH(alkyl), --N(alkyl).sub.2, --NH(C.dbd.)aryl, --NH--alkylene(NR.sub.8R.sub.9), --NH(C.dbd.O)-alkylene(NR.sub.8R.sub.9), --NR.sub.8(C.dbd.O), --NR.sub.8R.sub.9, --NH-alkylene-heteroaryl, --NHOH, --NHOCH.sub.3, --O-alkylene(NR.sub.8R.sub.9), alkyl, piperazine, fluoroalkyl, cyanoalkyl, cycloalkyl, fluorocycloalkyl, hydroxyalkyl, cyano, alkoxycarbonyl, carboxy, --(C.dbd.O)--(NR.sub.8R.sub.9), --(C.dbd.O)--NH-alkylene(NR.sub.8R.sub.9), and alkoxy; R.sub.2, R.sub.3, R.sub.4 and R.sub.5 are each independently selected hydrogen, alkyl fluoroalkyl, cyanoalkyl, cycloalkyl, fluorocycloalkyl, cycloalkoxyalkyl, alkylcycloalkyl, alkylfluorocycloalkyl, aryl, heteroaryl, heterocycle, O-aryl, O-heteroaryl, S-aryl, CONR.sub.8R.sub.9, NR.sub.8CO-alkyl, NR.sub.8(C.dbd.O)O-alkyl, acyl, acyloxy, alkenyl, alkoxy, alkoxyalkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxyimino, alkoxysulfonyl, alkylcarbonyl, alkylsulfonyl, alkynyl, amido, carboxy, cyano, fluoroalkoxy, formyl, haloalkoxy, haloalkyl, halogen, hydroxy, hydroxyalkyl, mercapto, nitro, alkylthio --NR.sub.8R.sub.9, -carbonyl(NR.sub.8R.sub.9), --SO.sub.2 NR.sub.8R.sub.9), and N(R.sub.8)SO.sub.2(R.sub.9), or R.sub.3 and R.sub.4 taken to ether are --CH.sub.2CH.sub.2CH.sub.2--, --CH.sub.2CH.sub.2CH.sub.2CH.sub.2--, or --CH.sub.2OCH.sub.2--; R.sub.6 is selected from hydrogen, alkyl, fluoroalkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, cycloalkyl, fluorocycloalkyl, cycloalkoxyalkyl, alkylcycloalkyl, and alkylfluorocycloalkyl; R.sub.7 is selected from fluoroalkyl, hydroxyalkyl, alkoxyalkyl, fluorocycloalkyl, and alkylfluorocycloalkyl; R.sub.8 and R.sub.9 are each independently selected from hydrogen, alkyl, fluoroalkyl, cycloalkyl, cyanoalkyl, fluorocycloalkyl, cycloalkoxyalkyl, alkylcycloalkyl, alkylfluorocycloalkyl, aryl, heteroaryl, heterocycle, acyl, alkoxyalkyl, alkoxycarbonyl, alkylcarbonyl, alkylsulfonyl, amido, formyl, hydroxy, and hydroxyalkyl; A.sub.1 is a group of structure A.sub.2 or A.sub.3 wherein A.sub.2 is selected from ##STR00046## ##STR00047## ##STR00048## and A.sub.3 is selected from ##STR00049## wherein G.sub.3 is O, S, S(O), or S(O).sub.2; n is 1, 2, or 3; and m is 0, 1, or 2; wherein each carbon atom of groups A.sub.1 may be optionally substituted with one or more groups selected from alkyl, fluoroalkyl, cyanoalkyl, cycloalkyl, fluorocycloalkyl, cycloalkoxyalkyl, alkylcycloalkyl, alkylfluorocycloalkyl, fluorine, acyl, acyloxy, alkenyl, alkoxy, alkoxyalkoxy, alkoxyalkyl, alkoxycarbonyl, alkylcarbonyl, alkylsulfonyl, alkynyl, amido, carboxy, cyano, fluoroalkoxy, formyl, haloalkoxy, haloalkyl, halogen, hydroxy, hydroxyalkyl, mercapto, nitro, and alkylthio; provided that when G.sub.1 is CH.sub.2CH.sub.2 and G.sub.2 is CH.sub.2 and R.sub.1 is selected from NH.sub.2, NHalkyl or alkyl, then A.sub.1 is not a group of structure K. 2. The method of claim 1, wherein the pain is inflammatory pain, inflammatory hyperalgesia, hyperalgesia, neuropathic pain, migraine, cancer pain, visceral pain, osteoarthritis pain, or post-surgical pain. 3. The method of claim 1, wherein the pain is neuropathic pain, migraine, cancer pain, visceral pain, osteoarthritis pain, or post-surgical pain. 4. The method of claim 1, wherein the pain is neuropathic pain, osteoarthritis pain, or post-surgical pain. 5. The method of claim 1, wherein the pain is osteoarthritis pain. 6. The method of claim 1, wherein the pain is post-surgical pain. 7. The method of claim 1, wherein the pain is neuropathic pain. 8. The method of claim 1, wherein the neuropathic pain is peripheral neuropathic pain syndrome, chemotherapy-induced neuropathy, complex regional pain syndrome, HIV sensory neuropathy, neuropathy secondary to tumor infiltration, painful diabetic neuropathy, phantom limb pain, postherpetic neuralgia, postmastectomy pain, trigeminal neuralgia, central neuropathic pain syndrome, central poststroke pain, multiple sclerosis pain, Parkinson disease pain, or spinal cord injury pain. 9. The method of claim 1, wherein the compound is 4-((R)-3-amino-pyrrolidin-1-yl)-6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-d- ]pyrimidin-2-ylamine; 4-piperazin-1-yl-6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-d]pyrimidin-2-yl amine; or 4-(3-methylamino-azetidin-1-yl)-6,7-dihydro-5H-benzo[6,7]cycloh- epta-[1,2-d]pyrimidin-2-ylamine. 10. The method of claim 1, wherein the compound of Formula (VI) or the salt thereof is administered, in combination with at least one selected from a histamine H.sub.1 antagonist; a histamine H.sub.2 antagonist, histamine H.sub.3 antagonist; a modulator of TNF-.alpha., an anti-inflammatory corticocosteroid; a 5-lipoxygenase inhibitor; a leukotriene antagonist; a LTB4 antagonist; a non-steroidal anti-inflammatory drug; a COX-2 inhibitor; an anti-nociceptive opiate agonist, an anti-nociceptive alpha adrenergic agonist, a TRPV1 antagonist, a nicotinic acetylcholine receptor agonist, a CB-1 agonist; a CB-2 agonist; a P2X7 antagonist; and a metabotropic glutamate receptor antagonist. 11. The method of claim 3, wherein the compound is 4-((R)-3-amino-pyrrolidin-1-yl)-6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-d- ]pyrimidin-2-ylamine; 4-piperazin-1-yl-6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-d]pyrimidin-2-yl- -amine; or 4-(3-methylamino-azetidin-1-yl)-6,7-dihydro-5H-benzo[6,7]cycloh- epta-[1,2-d]pyrimidin-2-ylamine. 12. The method of claim 1, wherein G.sub.1 is --CH.sub.2--, --CH.sub.2CH.sub.2--, --CH.sub.2CH.sub.2CH.sub.2--, or --CH.sub.2CH.sub.2CH.sub.2CH.sub.2--, and G.sub.2 is --CH.sub.2-- or --CH(CH.sub.3)--. 13. The method of claim 1, wherein R.sub.1 is selected from H, --NH.sub.2, --NHCH.sub.3, ##STR00050## 14. The method of claim 1, wherein A.sub.1 is selected from ##STR00051## ##STR00052## 15. The method of claim 1, wherein R.sub.2, R.sub.3, R.sub.4, and R.sub.5 are independently selected from H, fluoro, methyl, methoxy, pyridin-3-yl, phenyl, --(C.dbd.O)OCH.sub.3, cyano, --NHCH.sub.3, --NH(C.dbd.O)CH.sub.3, and ##STR00053## 16. The method of claim 1, wherein the compound is selected from 6-Methyl-4-[(3R)-3-methylamino-pyrrolidin-1-yl]-5,6-dihydro-benzo[h]quina- zolin-2-ylamine; 6-Methyl-4-(3-methylamino-azetidin-1-yl)-5,6-dihydro-benzo[h]quinazolin-2- -ylamine; 6-Methyl-4-piperazin-1-yl-5,6-dihydro-benzo[h]quinazolin-2-ylami- ne; 4-(3-(R)-Methylamino-pyrrolidin-1-yl)-5,6-dihydro-benzo[h]quinazolin-2- -ylamine; 4-(3-Methylamino-azetidin-1-yl)-5,6-dihydro-benzo[h]quinazolin-2- -ylamine; 4-piperazin-1-yl-5,6-dihydro-benzo[h]quinazolin-2-ylamine; (2,6-Diaza-spiro[3.5]non-2-yl)-6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-d]- pyrimidin-2-ylamine; N.sup.4-(2-azetidin-2-ylethyl)-6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-d]- pyrimidine-2,4-diamine; N.sup.4-[(2R)-azetidin-2-ylmethyl]-6,7-dihydro-5H-benzo[6,7]cyclohepta[1,- 2-d]pyrimidine-2,4-diamine; N.sup.4-(1-methylpiperidin-4-yl)-6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-- d]pyrimidine-2,4-diamine; N.sup.4-(3-Piperidin-1-yl-propyl)-6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2- -d]pyrimidine-2,4-diamine; N.sup.4-Piperidin-3-yl-6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-d]pyrimidi- ne-2,4-diamine; N.sup.4-(Octahydro-isoindol-4-yl)-6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2- -d]pyrimidine-2,4-diamine; N.sup.4-[(1R,5S)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]-6,7-dihydro-5H-ben- zo[6,7]cyclohepta[1,2-d]pyrimidine-2,4-diamine; 4-(3-Methylamino-azetidin-1-yl)-6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-d- ]pyrimidin-2-ylamine; 4-(3-(R)-Methylamino-pyrrolidin-1-yl)-6,7-dihydro-5H-benzo[6,7]cyclohepta- [1,2-d]pyrimidin-2-ylamine; 4-piperazin-1-yl-6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-d]pyrimidin-2-yl- amine; 10-Fluoro-4-(3-(R)-methylamino-pyrrolidin-1-yl)-6,7-dihydro-5H-benz- o[6,7]cyclohepta[1,2-d]pyrimidin-2-ylamine; 10-Fluoro-4-(3-methylamino-azetidin-1-yl)-6,7-dihydro-5H-benzo[6,7]cycloh- epta[1,2-d]pyrimidin-2-ylamine; 10-Fluoro-4-piperazin-1-yl-6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-d]pyri- midin-2-ylamine; 4-[(3S)-3-Methylamino-pyrrolidin-1-yl]-6,7-dihydro-5H-benzo[6,7]cyclohept- a[1,2-d]pyrimidin-2-ylamine; 4-((3R)-3-Amino-pyrrolidin-1-yl)-6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-- d]pyrimidin-2-ylamine; 4-(3-Piperidin-1-yl-pyrrolidin-1-yl)-6,7-dihydro-5H-benzo[6,7]cyclohepta[- 1,2-d]pyrimidin-2-ylamine; 4-(1,5-Diazocan-1-yl)-6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-d]pyrimidin- -2-amine; 4-(4-Aminopiperidin-1-yl)-6,7-dihydro-5H-benzo[6,7]cyclohepta[1,- 2-d]pyrimidin-2-amine; 4-(5-Methyl-1,4-diazepan-1-yl)-6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-d]- pyrimidin-2-amine; 4-((R)-3-Dimethylamino-pyrrolidin-1-yl)-6,7-dihydro-5H-benzo[6,7]cyclohep- ta[1,2-d]pyrimidin-2-ylamine; N-(4-piperazin-1-yl-6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-d]pyrimidin-2- -yl)-acetamide; N-(4-piperazin-1-yl-6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-d]pyrimidin-2- -yl)-benzamide; 2-Dimethylamino-N-(4-piperazin-1-yl-6,7-dihydro-5H-benzo[6,7]cyclohepta[1- ,2-d]pyrimidin-2-yl)-acetamide; 2-Methylamino-N-(4-piperazin-1-yl-6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2- -d]pyrimidin-2-yl)-acetamide; 2-Amino-N-(4-piperazin-1-yl-6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-d]pyr- imidin-2-yl)-acetamide; 1-Methyl-3-(4-piperazin-1-yl-6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-d]py- rimidin-2-yl)-urea; 4-Amino-N-(4-piperazin-1-yl-6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-d]pyr- imidin-2-yl)-butyramide; 3-Amino-N-(4-piperazin-1-yl-6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-d]pyr- imidin-2-yl)-propionamide; 4-[1,4,7]Triazonan-1-yl-6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-d]pyrimid- in-2-ylamine; N,N-Dimethyl-N'-(4-piperazin-1-yl-6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2- -d]pyrimidin-2-yl)-ethane-1,2-diamine; 4-((R)-3-Methylamino-pyrrolidin-1-yl)-6,7,9,10,11,12-hexahydro-5H-1,3-dia- za-benzo[3,4]cyclohepta[1,2-b]naphthalen-2-ylamine; 4-piperazin-1-yl-6,7,9,10,11,12-hexahydro-5H-1,3-diaza-benzo[3,4]cyclohep- ta[1,2-b]naphthalen-2-ylamine; 2,4-Dipiperazin-1-yl-6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-d]pyrimidine- ; 4-(4-Dimethylamino-piperidin-1-yl)-6,7-dihydro-5H-benzo[6,7]cyclohepta[1- ,2-d]pyrimidin-2-ylamine; 4-[1,4]Diazepan-1-yl-6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-d]pyrimidin-- 2-ylamine; 4-piperazin-1-yl-6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-d]pyri- midine; Methyl-(4-piperazin-1-yl-6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-d- ]pyrimidin-2-yl)-amine; 4-(3-(R)-Methylamino-pyrrolidin-1-yl)-6,7-dihydro-5H-benzo[6,7]cyclohepta- [1,2-d]pyrimidine; [1-(6,7-Dihydro-5H-benzo[6,7]cyclohepta[1,2-d]pyrimidin-4-yl)-azetidin-3-- yl]-amine; 8,10-Dimethyl-4-piperazin-1-yl-6,7-dihydro-5H-benzo[6,7]cyclohe- pta[1,2-d]pyrimidin-2-ylamine; (2-Amino-4-piperazin-1-yl-6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-d]pyrim- idin-10-yl)-methyl-carbamic acid methyl ester; 10-N-Methyl-4-piperazin-1-yl-6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-d]py- rimidine-2,10-diamine; (2-Amino-4-octahydro-pyrrolo[3,4-b]pyridin-6-yl-6,7-dihydro-5H-benzo[6,7]- cyclohepta[1,2-d]pyrimidin-10-yl)-methyl-carbamic acid methyl ester; 10-N-methyl-4-[(4aR,7aR)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-6,7-dih- ydro-5H-benzo[6,7]cyclohepta[1,2-d]pyrimidine-2,10-diamine; N-(2-Amino-4-piperazin-1-yl-6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-d]pyr- imidin-11-yl)-acetamide; 4-((3aR,6aR)-1-Methyl-hexahydro-pyrrolo[3,4-b]pyrrol-5-yl)-6,7-dihydro-5H- -benzo[6,7]cyclohepta[1,2-d]pyrimidin-2-ylamine; 4-((1S,4S)-2,5-Diazabicyclo[2.2.1]hept-2-yl)-6,7-dihydro-5H-benzo[6,7]cyc- lohepta[1,2-d]pyrimidin-2-ylamine; 4-((3aR,6aR)-Hexahydropyrrolo[3,4-b]pyrrol-1-yl)-6,7-dihydro-5H-benzo[6,7- ]cyclohepta[1,2-d]pyrimidin-2-ylamine; 4-(Hexahydropyrrolo[3,4-c]pyrrol-2-yl)-6,7-dihydro-5H-benzo[6,7]cyclohept- a[1,2-d]pyrimidin-2-yl-amine; 4-Octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl-6,7-dihydro-5H-benzo[6,7]cycloh- epta[1,2-d]pyrimidin-2-amine; 4-(2,8-Diazaspiro[4.5]dec-8-yl)-6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-d- ]pyrimidin-2-amine; 4-(1,9-Diazaspiro[5.5]undec-9-yl)-6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2- -d]pyrimidin-2-ylamine; 4-(2,5-Diazaspiro[3.5]non-2-yl)-6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-d- ]pyrimidin-2-ylamine; 4-(Octahydropyrrolo[3,4-c]pyridin-2-yl)-6,7-dihydro-5H-benzo[6,7]cyclohep- ta[1,2-d]pyrimidin-2-ylamine; 4-(Octahydropyrrolo[1,2-a]pyrazin-2-yl)-6,7-dihydro-5H-benzo[6,7]cyclohep- ta[1,2-d]pyrimidin-2-ylamine; 4-(3,6-Diazabicyclo[3.2.1]oct-6-yl)-6,7-dihydro-5H-benzo[6,7]cyclohepta[1- ,2-d]pyrimidin-2-ylamine; 4-(2,6-Diazabicyclo[3.2.1]oct-2-yl)-6,7-dihydro-5H-benzo[6,7]cyclohepta[1- ,2-d]pyrimidin-2-ylamine; 4-(5-Methyl-octahydro-pyrrolo[3,4-c]pyridin-2-yl)-6,7-dihydro-5H-benzo[6,- 7]cyclohepta[1,2-d]pyrimidin-2-ylamine; 4-(3-Methyl-3,6-diaza-bicyclo[3.2.1]oct-6-yl)-6,7-dihydro-5H-benzo[6,7]cy- clohepta[1,2-d]pyrimidin-2-ylamine; 6-(2-Pyridin-3-ylmethylamino-6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-d]py- rimidin-4-yl)octahydro-1H-pyrrolo[3,4-b]pyridine; 4-(Octahydro-pyrrolo[3,4-b]pyridin-6-yl)-6,7,9,10,11,12-hexahydro-5H-1,3-- diaza-benzo[3,4]cyclohepta[1,2-b]naphthalen-2-ylamine; 10-Fluoro-4-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl-6,7-dihydro-5H-benzo[- 6,7]cyclohepta[1,2-d]pyrimidin-2-amine; (1R,5S)-4-(3,6-Diaza-bicyclo[3.2.0]hept-6-yl)-6,7-dihydro-5H-benzo[6,7]cy- clohepta[1,2-d]pyrimidin-2-ylamine; (3aS,6aS)-4-(Hexahydro-pyrrolo[3,4-b]pyrrol-1-yl)-6,7-dihydro-5H-benzo[6,- 7]cyclohepta[1,2-d]pyrimidin-2-ylamine; (1S,5S)-4-(3,6-Diaza-bicyclo[3.2.0]hept-3-yl)-6,7-dihydro-5H-benzo[6,7]cy- clohepta[1,2-d]pyrimidin-2-ylamine; 6-(2-(1H-imidazol-4-yl)ethylamino-6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2- -d]pyrimidin-4-yl)octahydro-1H-pyrrolo[3,4-b]pyridine; 4-(Octahydro-pyrrolo[3,4-b]pyridin-6-yl)-6,7-dihydro-5H-benzo[6,7]cyclohe- pta[1,2-d]pyrimidine-2-carboxylic acid methyl ester; 4-(Octahydro-pyrrolo[3,4-b]pyridin-6-yl)-6,7-dihydro-5H-benzo[6,7]cyclohe- pta[1,2-d]pyrimidine-2-carboxylic acid; 4-piperazin-1-yl-5,6,7,8-tetrahydro-1,3-diaza-dibenzo[a,c]cycloocten-2-yl- amine; 4-[(3R)-3-(Methylamino)pyrrolidin-1-yl]-5,6,7,8-tetrahydrobenzo[7,8- ]cycloocta[1,2-d]pyrimidin-2-amine; 4-[(3R)-3-Aminopyrrolidin-1-yl]-5,6,7,8-tetrahydrobenzo[7,8]cycloocta[1,2- -d]pyrimidin-2-amine; 4-[(3S)-3-Aminopyrrolidin-1-yl]-5,6,7,8-tetrahydrobenzo[7,8]cycloocta[1,2- -d]pyrimidin-2-amine; 4-(3-Aminoazetidin-1-yl)-5,6,7,8-tetrahydrobenzo[7,8]cycloocta[1,2-d]pyri- midin-2-amine; 4-[(3aR,6aR)-Hexahydropyrrolo[3,4-b]pyrrol-1(2H)-yl]-5,6,7,8-tetrahydrobe- nzo[7,8]cycloocta[1,2-d]pyrimidin-2-amine; 4-piperazin-1-yl-6,7,8,9-tetrahydro-5H-1,3-diaza-dibenzo[a,c]cyclononen-2- -ylamine; 4-(3-(R)-Methylamino-pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-1,3-- diaza-dibenzo[a,c]cyclononen-2-ylamine; 4-((R)-3-Amino-pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-1,3-diaza-dibenzo[a- ,c]cyclononen-2-ylamine; 4-((S)-3-Amino-pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-1,3-diaza-dibenzo[a- ,c]cyclononen-2-ylamine; 4-(3-Methylamino-azetidin-1-yl)-6,7,8,9-tetrahydro-5H-1,3-diaza-dibenzo[a- ,c]cyclononen-2-ylamine; 4-((3aS,6aS)-Hexahydro-pyrrolo[3,4-b]pyrrol-1-yl)-6,7,8,9-tetrahydro-5H-1- ,3-diaza-dibenzo[a,c]cyclononen-2-ylamine; and 4-((1S,4S)-2,5-Diaza-bicyclo[2.2.1]hept-2-yl)-6,7,8,9-tetrahydro-5H-1,3-d- iaza-dibenzo[a,c]cyclononen-2-ylamine. 17. The method of claim 1, wherein the compound is selected from 4-((S)-Pyrrolidin-3-yloxy)-6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-d]pyri- midin-2-ylamine; 4-((S)-1-Methyl-pyrrolidin-3-yloxy)-6,7-dihydro-5H-benzo[6,7]cyclohepta[1- ,2-d]pyrimidin-2-ylamine; 4-(1-Methyl-piperidin-4-yloxy)-6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-d]- pyrimidin-2-ylamine; 4-(Piperidin-4-yloxy)-6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-d]pyrimidin- -2-ylamine; 4-(1-Methyl-piperidin-3-yloxy)-6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-d]- pyrimidin-2-ylamine; 4-(2-Dimethylamino-ethoxy)-6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-d]pyri- midin-2-ylamine; and 4-((R)-1-Methyl-pyrrolidin-3-yloxy)-6,7-dihydro-5H-benzo[6,7]cyclohepta[1- ,2-d]pyrimidin-2-ylamine.

Details for Patent 7,985,745

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Jubilant Hollisterstier Llc	N/A	positive skin test control-histamine	Injection	103891	03/13/1924		2026-10-02